Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Pragmat Obs Res ; 12: 49-63, 2021.
Article in English | MEDLINE | ID: mdl-34163283

ABSTRACT

INTRODUCTION: Successful treatment for serious mental illnesses (SMIs) requires a good therapeutic alliance with healthcare providers and compliance with prescribed therapies such as antipsychotic medications. This retrospective study, which utilized administrative claims linked with abstracted medical chart data, addressed a data gap regarding compliance-related discussions between providers and patients. METHODS: Commercially insured patients in ambulatory care post-acute (emergency or inpatient) event were eligible. Criteria included age 18-65 years; schizophrenia, bipolar disorder, or major depressive disorder diagnoses; continuous enrollment 6 months before to 12 months after the first acute event claim dated 01/01/2014 to 12/31/2015; and antipsychotic medication prescription. Demographic and clinical data, and patient-provider discussions about treatment compliance were characterized from claims and abstracted medical charts. RESULTS: Ninety patients (62% female, mean age 41 years) were included and 680 visits were abstracted; only 58% had first-visit antipsychotic compliance discussions. Notably, 18% of patients had discussions using the specific terms "compliance," "persistence," or "adherence," whereas half were identified by more general terms. Compliance discussions were observed least often among the patients with schizophrenia, as compared with bipolar or major depressive disorders-a counterintuitive finding. DISCUSSION: Compliance discussions may represent intervention opportunities to optimize treatment, yet their study is a complex endeavor. The results of this study show an opportunity to improve this valuable treatment step.

2.
Curr Med Res Opin ; 37(10): 1799-1809, 2021 10.
Article in English | MEDLINE | ID: mdl-34139902

ABSTRACT

OBJECTIVE: Serious mental illnesses (SMIs), including schizophrenia, bipolar disorder, and major depressive disorder (MDD), are often treated with antipsychotic medications. Unfortunately, medication non-adherence is widespread and is associated with serious adverse outcomes. However, little real-world data are available describing adherence, compliance, or other medication-taking-related discussions between providers and patients. This study described these communications in ambulatory care. METHODS: Commercially insured patients having acute (emergency or inpatient) behavioral health (BH) events were included by specific criteria: age 18-65 years; diagnoses of schizophrenia, bipolar disorder, or MDD; continuous health insurance coverage 6 months before to 12 months after the first claim (index) date during 01/01/2014‒12/31/2015; and prescribed antipsychotic medication. Medical charts were abstracted for ambulatory visits with a BH diagnosis through 12 months after the acute event, describing any treatment compliance discussions that occurred. BH-related healthcare utilization and costs were measured via insurance claims. Results were analyzed by observation of an antipsychotic medication taking-related (i.e. compliance or adherence) discussion at the initial abstracted visit. RESULTS: Ninety patients were included: 62% female, mean age 41 years. Only 58% had antipsychotic compliance discussions during the first abstracted ambulatory visit. A total of 680 BH-related visits were abstracted for the 90 patients. Providers frequently discussed any psychotropic medication use (97% of all visits abstracted); however, discussion of compliance with BH talk therapies was less common (49% of visits among patients with a first visit antipsychotic discussion and 23% without, p < .001). Follow-up BH-related healthcare utilization and costs were not significantly different by cohort. Patients with ≥2 compliance discussions had a significantly lower risk of follow-up acute events, which are the costliest components of healthcare for SMI (p = .023). CONCLUSION: Increasing the frequency of antipsychotic treatment-related adherence/compliance discussions may represent an opportunity to improve the quality of care for these vulnerable patients and reduce the overall economic burden associated with the treatment of SMI diagnosis.


Subject(s)
Antipsychotic Agents , Depressive Disorder, Major , Mental Disorders , Schizophrenia , Adolescent , Adult , Aged , Antipsychotic Agents/therapeutic use , Depressive Disorder, Major/drug therapy , Female , Health Care Costs , Humans , Male , Mental Disorders/drug therapy , Middle Aged , Patient Compliance , Retrospective Studies , Schizophrenia/drug therapy , Young Adult
3.
Ann Allergy Asthma Immunol ; 123(4): 381-388.e2, 2019 10.
Article in English | MEDLINE | ID: mdl-31325566

ABSTRACT

BACKGROUND: Systemic therapies are commonly used for patients with uncontrolled moderate-to-severe atopic dermatitis (AD) and impaired quality of life (QoL). However, real-world treatment patterns and unmet needs of adults with moderate-to-severe AD receiving systemic therapies are poorly quantified. OBJECTIVE: To evaluate unmet needs in patients with moderate-to-severe AD treated with systemic therapies. METHODS: Adults with AD diagnosis in past 5 years and a prescription for systemic treatment or phototherapy in past 6 months were identified from the Optum Research Database. Patients completed a survey about symptoms, treatment, and QoL. Chi-squared and t tests analyzed bivariable comparisons of demographics and outcomes. Spearman's rank-order correlation analyses examined the relationship between frequency of flares and outcomes. RESULTS: Eight hundred and one participants were included (mean age, 45.2 years; 71.8% female). In the 12 months before baseline survey, 38.3% reported no remission from AD. In the month before baseline survey, 63.6% used topical corticosteroids, and 81.3% of patients experienced 1 or more flares. Patients experiencing flares reported worse Patient-Orientated Eczema Measure (POEM), Peak Pruritus Numeric Rating Scale (NRS), and Dermatology Life Quality Index scores (DLQI), lower treatment satisfaction, and greater work productivity loss than patients without flares (all P < .001). Patients with severe atopic dermatitis reported worse POEM, Peak Pruritus NRS, and DLQI, lower treatment satisfaction, and greater work productivity loss than patients with moderate AD (all P < .001). CONCLUSION: Despite receiving systemic therapies, adults with moderate-to-severe AD reported disease symptoms, recurrent flares, and impaired QoL, suggesting unmet therapeutic needs.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Dermatitis, Atopic/therapy , Immunosuppressive Agents/therapeutic use , Patient Reported Outcome Measures , Patient Satisfaction/statistics & numerical data , Phototherapy/methods , Adult , Aged , Female , Humans , Longitudinal Studies , Male , Middle Aged , Prospective Studies , Quality of Life/psychology , Severity of Illness Index , Surveys and Questionnaires , Young Adult
4.
BMC Health Serv Res ; 18(1): 662, 2018 Aug 25.
Article in English | MEDLINE | ID: mdl-30144806

ABSTRACT

BACKGROUND: Prior research suggests that many patients do not spontaneously include work/income loss when responding to utility assessments, although this remains unconfirmed in the US due to almost no published US-based studies to date, and has not been previously studied among patients with herpes zoster (HZ). The objective of this study was to examine whether patients with HZ consider work and income loss when completing a quality of life survey. METHODS: A cross-sectional survey was administered to 2000 US adult commercial health plan enrollees aged 50-64 years with ≥ 1 HZ medical claim during 2014. The survey collected information related to health status (EQ-5D), work productivity, and HZ severity and clinical features. RESULTS: Mean respondent age was 58.4 years [standard deviation (SD) 4.1] and 62.0% were female. About 3 in 4 (76.8%) patients (N = 772) were employed either full (69.9%) or part time (6.9%). Less than half (45%) spontaneously considered work/income loss when responding to EQ-5D, and mean EQ-5D scores for patients who considered work/income loss were lower than for patients who did not [0.56 (SD = 0.28) vs. 0.69 (SD = 0.24); p < 0.001]. Overall, 43% of patients reported at least one full day missed (mean = 9 full days) and 29% reported at least one partial day missed (mean = 6 partial days) during the most recent shingles episode. Patients who considered work loss were more likely to have missed full (76.4% vs 26.0%, p < 0.001) or partial (70.9% vs. 35.2%, p < 0.001) days. Patients with absenteeism were more likely to consider work/income loss when completing EQ-5D [odds ratio (OR) = 7.91, 95% confidence interval (CI) 5.01-12.31]. Odds of absenteeism/presenteeism increased significantly with increasing levels of HZ severity, and higher odds were associated with pain located on the face/scalp/neck/eye/ear (OR 1.90, 95% CI 1.06-3.40) and with pain lasting 12+ months (OR = 2.91, 95% CI 1.14-7.42). CONCLUSIONS: HZ has considerable impact on the work and productivity of adults aged 50-64 years old. However, many patients with HZ do not spontaneously consider work/income loss when completing a standardized quality of life questionnaire. Studies that use health state utilities in HZ based on EQ-5D may not fully reflect the societal costs of work loss.


Subject(s)
Cost of Illness , Herpes Zoster , Income , Quality of Life , Absenteeism , Cross-Sectional Studies , Efficiency , Female , Health Status , Herpes Zoster/economics , Humans , Male , Middle Aged , Patient Acuity , Presenteeism/statistics & numerical data , Surveys and Questionnaires , United States
6.
J Womens Health (Larchmt) ; 15(3): 312-8, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16620190

ABSTRACT

BACKGROUND: There is limited information available regarding the characteristics of patients who elect to gather and share information about their malignancy on the Internet. METHODS: Using a proprietary decision support program embedded into a number of established websites, individuals entered personal clinical data into disease site profilers designed to provide information about evidence-based treatment options, based on specific characteristics (e.g., stage of disease, prior therapy) provided by the patients. The aggregate data were evaluated to examine the characteristics of patients with gynecological cancer (with a focus on newly diagnosed and recurrent ovarian cancer) using such a tool. RESULTS: From early 2000 through November 2004, >15,000 patients with gynecological cancer have entered data into one of four profilers: newly diagnosed (n = 5604)/recurrent (n = 2803) ovarian, endometrial, and cervical cancers. Internal data consistency includes similar ages and general health histories of the ovarian and endometrial cancer populations and younger age of the cervical cancer patients. Whereas 90% of the women with ovarian cancer considered themselves to be in "good health," 64% of newly diagnosed vs. only 50% of recurrent disease patients declared their activity level was "normal." Of the recurrent patients, 32% stated they had undergone a secondary surgery. The overall aggressive management philosophy of the recurrent patients in this series is supported by the observation that 33% had received > or =4 prior chemotherapy regimens, 97% desired additional treatment, and 81% were interested in clinical trials. CONCLUSIONS: Women with ovarian cancer seeking assistance from web-based decision support programs may represent a subgroup with unique clinical features compared with the general patient population.


Subject(s)
Decision Making , Internet , Ovarian Neoplasms/therapy , Patient Participation/statistics & numerical data , Women's Health , Adult , Clinical Trials as Topic , Endometrial Neoplasms/therapy , Female , Health Knowledge, Attitudes, Practice , Humans , Middle Aged , Ovarian Neoplasms/psychology , Surveys and Questionnaires , United States/epidemiology , Uterine Cervical Neoplasms/therapy
7.
J Cancer Res Clin Oncol ; 132(7): 439-43, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16538516

ABSTRACT

PURPOSE: As the Internet can potentially substantially reduce geographic barriers to the dissemination of health-related information, it would be interesting to know if non-American women with gynecologic malignancies accessing United States (US)-based cancer Web sites differ from American patients with the same illness. PATIENTS AND METHODS: Aggregate data from individuals providing personal clinical information into one of four proprietary gynecologic cancer (cervix, endometrial, newly diagnosed and recurrent ovarian cancers) decision-support programs (NexProfiler Treatment Option Tools for Cancer; NexCura Inc., Seattle WA, USA) currently embedded within approximately 100 established cancer-related Web sites were examined for differences between American versus non-American patient populations. RESULTS: In this analysis, which included >15,000 patients, American and non-American gynecologic cancer patients were remarkably similar in most clinical characteristics, including age, stage of disease at presentation, overall health, and desire to receive information regarding clinical trials. Notable differences included features suggestive of a more aggressive surgical philosophy in the US (e.g., higher percentage of American recurrent ovarian cancer patients reported they had undergone a secondary surgical procedure; greater use of radiotherapy in non-American cervical cancer patients). CONCLUSION: Despite differences in geographic location and health care delivery systems, American and non-American patients with gynecologic malignancies and with access to Internet-based cancer information exhibit few, but notable, differences in self-reported clinical characteristics.


Subject(s)
Decision Making , Decision Support Systems, Clinical/statistics & numerical data , Genital Neoplasms, Female/therapy , Information Dissemination , Internet , Adult , Australia , Canada , Endometrial Neoplasms/therapy , Female , Genital Neoplasms, Female/drug therapy , Genital Neoplasms, Female/radiotherapy , Genital Neoplasms, Female/surgery , Germany , Humans , India , Mexico , Middle Aged , Ovarian Neoplasms/therapy , Radiotherapy/statistics & numerical data , Second-Look Surgery/statistics & numerical data , United Kingdom , United States , Uterine Cervical Neoplasms/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...